Showing 21-30 of 1119 results for "".
To Be Shorr: Your receptionist is director of first impressions
https://practicaldermatology.com/topics/practice-management/to-be-shorr-your-receptionist-is-director-of-first-impressions/18603/Th best physicians and surgeons can see their practice fall apart if they lack good staff. The receptionist is often the first contact a patient has with your practice. Think of this individual as your director of first impressions, says Mara Shorr, BS, CAC II-V.To Be Shorr: Importance of Using Technology to Its Fullest Extent
https://practicaldermatology.com/topics/practice-management/to-be-shorr-importance-of-using-technology-to-its-fullest-extent/18605/Some of the administrative tasks that bog down a practice can be automated—and your existing vendors may have the applications and technology you need to make it happen. Be sure to investigate the services your vendors provide, many of which you already pay for, to make the most of your practice tecGive Yourself Credit...The Right Way
https://practicaldermatology.com/topics/practice-management/give-yourself-credit-the-right-way/18546/Credit card processing is widely misunderstood. Processing rates vary. BA, MBM-C, CAC I-IX explains how processing fees work and what you need to know to save money and optimize revenues.Treating Moderate to Severe Psoriasis: Weighing the Treatment Options
https://practicaldermatology.com/topics/psoriasis/-treating-moderate-to-severe-psoriasis-weighing-the-treatment-options/18375/In part 2 of her interview with DermTube Journal Club host Joshua Zeichner, MD, Erin Boh, MD reviews new biologics that provide patients with moderate to severe psoriasis improved treatment options. She discusses their efficacy and safety and offers tips for finding the right one for each patient baDermwireTV — Bayer Buys Merck’s OTC Lines, Allergan Rejects Valeant Bid
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-bayer-buys-merck-rsquo-s-otc-lines-allergan-rejects-valeant-bid/19134/Bayer Purchases Merck's OTC Products and Allergan Rebuffs Valeant. This week DermWireTV explores Bayer's growth in the OTC space, including sunscreens, and reports new data on skin cancer mortality. Also in this edition: Neal Bhatia, MD reviews the Noah Worcester Society Annual Meeting.Scientifically Speaking: Applying Energy-Based Devices Across Skin Tones
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-applying-energy-based-devices-across-skin-tones/19895/With advancements in technology and a patient-focused approach to treatment, it's possible to safely and effectively apply energy-based devices to a range of skin concerns in patients with darker skin. Host Joel L. Cohen, MD discusses treatment strategies for melasma, acne, PFB, scarring and more wiNRS: New Rosacea Classification; Pediatric Teledermatology; Bleach Baths
https://practicaldermatology.com/series/dermwire-tv/nrs-new-rosacea-classification-pediatric-teledermatology-bleach-baths/18394/There's a new standard classification and pathophysiology of rosacea from the National Rosacea Society. New evidence shows that virtual diagnosis of pediatric dermatologic conditions is feasible. New research suggests that water baths may be just as good as bleach baths for treating eczema. ResearchTaylor Made: One-of-a-kind Solutions for Device-based Services
https://practicaldermatology.com/topics/practice-management/taylor-made-one-of-a-kind-solutions-for-device-based-services/18789/An expert on the leading edge of device-based interventions, Mark B. Taylor, MD has learned when and how to adopt technologies and how to get the most from the systems in his practice. In this edition of Best Practices in Aesthetics, host Joel L. Cohen, MD asks Dr. Taylor to share his tips for optimCosentyx Approved, Silver is Bad for Burns
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-approved-silver-is-bad-for-burns/18971/FDA approves the first IL-17 inhibitor for psoriasis—Cosentyx from Noavartis, and new research explains why silver sulfadiazine is bad for burn wounds. Plus, we get an update on the Dermatology Summit and the state of innovation in dermatology, and learn about Phase III trials for Dermira's Cimzia.Take 5: Recent Findings on Barrier Function and Repair
https://practicaldermatology.com/columns/take-5/take-5-recent-findings-on-barrier-function-and-repair/21831/Data continue to elucidate the significance of the skin barrier in maintaining skin health and guide clinicians in the best approaches to barrier repair.